ABL1 and neoplasm: For instance, the tumor suppressor miR-7 directly targets the ABL1 3′UTR, and its transfection in the K562 CML cell line inhibits the proliferation, increases the apoptosis and enhances sensitivity to imatinib [166], a tyrosine kinase inhibitor (TKI) specific for the TK domain of ABL1 [167].